Year: 2025

Phase 1 data of first-in-class NBD1 stabilizers, SION-719 and SION-451, demonstrated they were generally well tolerated and exceeded desired pharmacokinetic targets New preclinical data show that NBD1 stabilizers restored the half-life of F508del-CFTR up to wild-type levels WALTHAM, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) — Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced data presented at the 2025 North American Cystic Fibrosis Conference (NACFC) being held in Seattle, Washington October 22-25. “We are focused on advancing therapies that have the potential to make...

WALTHAM, Mass. and BOULDER, Colo., Oct. 24, 2025 (GLOBE NEWSWIRE) — Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced updated preclinical data from the company’s potent and selective pan KRAS(ON) inhibitor in a poster presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place in Boston, MA, October 22-26, 2025.  “We are excited today to share updated data from our pan KRAS(ON) program which demonstrates a potential best-in-class profile for our lead molecule,” said Andrew Robbins, Cogent’s President and Chief Executive Officer. “We look forward to advancing this program with the goal of filing an Investigational New Drug (IND) application to the U.S. Food and...

—Strategic Shift Focuses on Stablecoin Infrastructure and RWA TrackHong Kong, Oct. 24, 2025 (GLOBE NEWSWIRE) — SOLOWIN HOLDINGS (NASDAQ: AXG) (“Solowin” or the “Company”), a leading financial services firm bridging traditional and digital assets, today announced the celebration of its first trade under the new ticker symbol “AXG” with a bell-ringing ceremony at the Nasdaq Stock Exchange. The event brought together long-term investors, strategic partners, and senior executives, marking a significant milestone in the Company’s strategic evolution. Addressing the audience, Dr. Haokang Thomas Zhu, director of Solowin, stated: “AXG stands for more than just a name — it reflects our bold vision to build a ‘Super App’ that seamlessly connects the traditional and digital financial worlds.” Through the advancement of its stablecoin infrastructure...

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Clariant Board of Directors decided to reduce its size and enhance corporate governance Muttenz, 24 October 2025 Clariant, a sustainability-focused specialty chemical company, today announced that the Board of Directors decided to reduce its size from eleven to eight members, right-sizing the Board to align with Clariant’s streamlined operations and addressing investor concerns on independence, tenure and gender diversity. In support of these efforts, five directors, Roberto Gualdoni, Geoffery Merszei, Eveline Saupper, Peter Steiner, and Konstantin Winterstein will not stand for reelection at the 2026 AGM on 1 April 2026. The Board will propose two new, independent Board members to the shareholders as appropriate ahead of the 2026 AGM. The Board’s independent Chairman, Ben van Beurden...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. (Ålesund, 24 October 2025) Reference is made to the stock exchange notices published by Hofseth BioCare ASA (“HBC” or the “Company“) earlier today regarding the launch of a private placement in the amount of between NOK 155m and NOK 181m and the partial divestment of shares in its U.S. subsidiary AecorBio Inc. (“AecorBio“). In conjunction with the Private Placement, the Company has resolved to divest 1,616,498 shares in AecorBio for approx. USD 5 million at a price per share of USD 3.0931,...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Hofseth BioCare ASA (“HBC” or the “Company“) today announces a contemplated private placement (the “Private Placement“) of between 86,096,132 and 100,638,889 new shares (“Offer Shares“) at a fixed price per share of NOK 1.80 (the “Offer Price“) corresponding to a total Private Placement size of between approx. NOK 155 million and approx. 181 million (the “Offer Size“). An amount fully covering the lower end of the Offer Size has already been placed...

October 24, 2025 MONTHLY DISCLOSURE OF THE TOTAL NUMBER OF SHARES AND VOTING RIGHTS Articles L. 233-8 II of the Commercial Code and 223-16 of the General Regulation of the AMFDate   Shares   Voting rightsTheoretical* Exercisable**30 September 2025 43,203,225 48,979,191 48,925,369*This number is calculated on the basis of all the shares to which voting rights are attached, including shares which voting rights have been suspended, in accordance with Article 223-11 of the AMF general regulation related to the calculation of the crossing of thresholds with regard to the number of voting rights. **For information purposes, this number excludes the shares which voting rights have been suspended. The information is also available in the « Regulated Information » section of the Ipsos website: https://www.ipsos.com/en/regulated-informations/en....

PRESS RELEASE Brussels, 24 October 2025 (17.45)World leader in aluminium anodisingCHANGES IN COIL’S GOVERNANCE COIL, the world leader in aluminium anodising, is reshaping its governance to accelerate its transformation and enhance operational leadership in a challenging market environment. At its meeting on 16 October 2025, the Board of Directors of COIL decided to terminate the contract with Finance & Management International (FMI), represented by Timothy Hutton, which had until now been responsible for the Company’s executive management. At the same time, the Board appointed Jean Schroyen (representing SIMAC Solutions BV) and Jan Robeyns (representing J2Fix BV) as Managing Directors, in charge of day-to-day operations and the implementation of the recovery plan currently underway. Deeply rooted in COIL’s history and industrial...

24 October 2025 | SAINT HELIER, Jersey | CoinShares International Limited (“CoinShares” or “the Group”) (Nasdaq Stockholm: CS; US OTCQX: CNSRF), the leading European asset manager specialising in digital assets, announces a change to its financial calendar following the receipt of a waiver granted by Nasdaq Stockholm regarding publication of the Group’s financial results for the interim period 1 January – 30 September, 2025 (Q3). As a result of this waiver, CoinShares will not publish its financial results for Q3 2025 which was set to be published on November 11, 2025. CoinShares’ Q3 2025 performance remained strong, building on the momentum communicated in previous updates. The quarter reflected both favorable industry conditions and sustained investor confidence in our platform.  As previously announced...